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Abstract. Fungal metabolites continue to show promise as
a viable class of anticancer agents. In the present study, we
investigated the efficacy of the fungal metabolite, fusarochromanone (FC101), for its antitumor activities in glioblastomas,
which have a median survival of less than two years and a poor
clinical response to surgical resection, radiation therapy and
chemotherapy. Using clinically applicable doses, we demonstrated that FC101 induced glioblastoma apoptotic cell death
via caspase dependent signaling, as indicated by the cleavage
of poly(ADP-ribose) polymerase, glioblastoma (PARP). FC101
also induced differential reactive oxygen species (ROS) levels
in glioblastoma cells, contrasting a defined role of oxidative
stress in apoptotic cell death observed with other fungal
metabolites. Furthermore, the antitumorigenic effects of
FC101 on tumor cell migration were assessed. Cell migration
assays revealed that FC101 significantly reduced the migratory capacity of glioblastomas, which are incredibly invasive
tumors. Taken together, the present study establishes FC101 as
a candidate anticancer agent for the cooperative treatment of
glioblastomas.
Introduction
Fungal metabolites are naturally occurring compounds
produced by fungi with known anticancer properties (1). This is
supported by early studies on cytochalasins, fungal metabolites
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that have been shown to inhibit the growth and migration of
prostate cancer cells (2), as a consequence of impairing the
biophysical function of actin filaments by binding and capping
their barbed ends, thus, preventing microfilament elongation.
Additionally, secondary metabolites (phenolic compounds,
melanins and lanostane-type triterpenoids) produced by
the white rot fungus, Inonotus obliquus, have also exhibited
antitumorigenic properties in breast, leukemia and gastric
cancers (3-5). Collectively, these studies provide experimental
evidence for the persistent exploration and utility of fungal
metabolites as agents for the treatment of human cancers.
In the present study, we evaluated the efficacy of fusarochromanone (FC101), a fungal metabolite produced by
Fusarium equiseti (6), in glioblastoma, the most common and
aggressive type of malignant primary brain tumor. To date, few
studies have been performed that have assessed the efficacy of
FC101 as an anticancer agent. However, experimental studies
conducted by Furmanski et al (7) and Dréau et al (8) have
demonstrated that FC101 inhibits the growth of breast cancer
cells and the in vitro and in vivo growth of melanomas. In addition a recent study by our group [Mahdavian et al (unpublished
data)] also demonstrated that FC101 exerts antitumor affects in
prostate and bladder cancer, further establishing the anticancer
activity of this fungal metabolite. To this end, although the
usage of fungal metabolites as potential therapeutic agents
for the treatment of glioblastomas has received little attention,
in this study, we provide evidence of the antitumor effects of
FC101 on glioblastoma cell proliferation through the promotion of apoptotic cell death, as well as its antagonizing affects
on glioblastoma cell migration.
Materials and methods
Cell conditions and reagents. U87, A172 and U251 glioblastoma cells were purchased from the American Type
Culture Collection (ATCC; Manassas, VA, USA). All cell
lines were maintained in Dulbecco's modified Eagle's
medium-DMEM (Invitrogen, Grand Island, NY, USA)
containing 10% fetal bovine serum (FBS; Invitrogen), 2 mM
L-glutamine (Invitrogen), 100 nM MEM non-essential amino
acids (Invitrogen) and penicillin-streptomycin (Invitrogen)
at 37˚C and 5% CO2. FC101 was generously provided by
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Dr Elahe Mahdavian (Department of Chemistry and Physics,
LSU-Shreveport, Shreveport, LA, USA).
Crystal violet cell proliferation assay. The cells were plated
in 24-well plates, treated with 10, 5, 2.5 and 1 µM FC101 and
allowed to incubate for 48 h (vehicle controls were treated
with PBS) for dose-response experiments. For time-course
experiments, the cells were treated with 1 µM FC101 and
allowed to incubate for 24, 48, 72 and 96 h. Subsequently, the
tissue culture medium was removed, the cell monolayer was
fixed with 100% methanol for 5 min and stained with 0.5%
crystal violet in 25% methanol for 10 min. The cells were then
washed 3 times for 5 min each with distilled water to remove
excess dye and allowed to dry overnight at room temperature.
The incorporated dye was then solubilized in 0.1 M sodium
citrate (Sigma-Aldrich, St. Louis, MO, USA) in 50% ethanol.
Subsequently, 100 µl of treated and control samples were
transferred to 96-well plates and optical densities were read
at 540 nm using an xMark Microplate absorbance spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA).
Cell motility. Motility assays were conducted according to the
manufacturer's instructions (Cell Biolabs Inc., San Diego, CA,
USA). A cell suspension containing 0.5-1.0x106 cells/ml was
prepared in serum-free mediaum with the vehicle (PBS) or
1 µM FC101, while 500 µl of medium containing 10% fetal
bovine serum was added to the lower chamber of the migration
plate. Cell suspension (300 µl) containing the vehicle or 1 µM
FC101 was then added to the inside of each insert and allowed
to incubate for 24 h at 37˚C and 5% CO2. Subsequently, the
non-migratory cells were removed from the plate inserts (as per
the manufacturer's instructions), and the migratory cells were
counterstained, solubilized and the optical density densities
were read at 560 nm using an xMark Microplate absorbance
spectrophotometer (Bio-Rad Laboratories).
Measurement of reactive oxygen species (ROS; H2O2) generation. ROS assays were conducted in accordance with the
manufacturer's instructions (Cell Biolabs Inc.). A serial dilution of H2O2 (0-100 µM) was prepared to generate a standard
curve, while the U87 and A172 cells (1x107) were plated,
exposed to 1 µM FC101 or the vehicle (PBS) for 24 h and sonicated. Standards and samples were then mixed with an aqueous
working reagent (as per the manufacturer's instructions), incubated on a shaker for 30 min at room temperature, and the
optical densities were read at 595 nm with a xMark Microplate
absorbance spectrophotometer (Bio-Rad Laboratories).
ELISA. The cells were plated and treated with 1 µM FC101
for 24 h or the vehicle (PBS); the cells were then lysed with
CelLytic M Cell lysis reagent (Sigma-Aldrich) and protein
concentrations were determined using the Bradford method.
Protein extracts were diluted to a final concentration of 20 µg/
ml in PBS, coated to the wells of a PVC microtiter plate, and
allowed to incubate at 4˚C overnight. Wells containing protein
antigen were then washed with PBS 3 times, blocked with
5% non-fat dry milk in PBS for 2 h, and washed again with PBS
2 times. Subsequently, incubation with α-actinin 1 (Abnova,
Walnut, CA, USA) or α-actinin 4 (Abnova) antibodies was
performed overnight at 4˚C followed by washing 4 times with
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PBS. Incubation with an HRP-conjugated secondary antibody
was performed for 3 h, followed by 4 washes with PBS. TMB
substrate solution (Thermo Fisher Scientific, Inc., Rockford,
IL, USA) was added for 15 min followed by a stop reaction
with 0.2 M sulfuric acid. An absorbance reading at 450 nm
was performed with a xMark Microplate absorbance spectrophotometer (Bio-Rad Laboratories). Absorbance readings
were normalized to FC101 and the vehicle-treated samples
that were processed with secondary antibody only.
Western blot analysis. The cells were plated and treated with
1 µM FC101 for 24 h or the vehicle (PBS), rinsed with PBS,
and lysed with CelLytic M Cell lysis reagent (Sigma-Aldrich).
Protein concentrations were subsequently determined using
the Bradford method. Proteins were separated by SDS-PAGE
in 8% polyacrylamide gels, then transferred to PVDF
membranes. For immunoblotting, the PVDF membranes were
incubated with poly(ADP-ribose) polymerase (PARP) and
caspase-9 antibodies (Cell Signaling Technology, Danvers,
MA, USA) recognizing target proteins overnight at 4˚C. The
membranes were then incubated with an HRP-conjugated
secondary antibody (1:2,000) for 1 h at room temperature,
analyzed using the enhanced chemiluminescence (ECL)
detection system (Thermo Fisher Scientific) and visualized
by autoradiography. Tubulin (1:5,000) was used as a loading
control.
Results
Antiproliferative effects of FC101 on glioblastomas. Our initial
experiments evaluated the effects of FC101 on glioblastoma
cell proliferation in dose-response experiments that showed
that FC101 (10, 5, 2.5 and 1 µM) decreased the proliferative
capacity of the U87, A172 and U251 cells (Fig. 1). The most
demonstrative effects of FC101 in dose-response experiments
were observed in the U251 cells which displayed a statistically
significant decrease (P<0.05) in cell proliferation, even when
treated with the lowest dose of 1 µM FC101, as compared to
the vehicle-treated control cells (Fig. 1). To further assess the
effects of FC101 on glioblastoma cell proliferation, time-course
experiments were performed in which the cells were treated
with 1 µM FC101 and examined over a 4-day period (Fig. 2).
Consistent with the results from the dose-response experiments, time-course analysis also revealed that FC101 reduced
the proliferation of the glioblastoma cells, as evidenced by a
pronounced decrease in cell proliferation 96 h post-FC101
exposure, as compared to the vehicle-treated control cells
examined at the same time point (Fig. 2). Additionally, ANOVA
analysis of the time-course data revealed that the statistically
significant (P<0.05) decrease observed in glioblastoma cell
proliferation following treatment with FC101 was likely a
consequence of a cytotoxic cellular response. This was determined by comparing glioblastoma cell viability at day 0 and
4 days post-FC101 exposure, which showed a 31, 66 and 82%
decrease in U87, A172 and U251 cell proliferation, respectively
(Fig. 2). These data are in accordance with those of previous
studies on FC101 in melanomas and breast cancer (7,8), as well
as with those of studies conducted on glioblastomas with the
fungal metabolites, ophiobolin A (9) and fumonisin B1 (10-12)
that also induced cytotoxic cellular responses.
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Figure 1. Fusarochromanone (FC101) inhibits glioblastoma cell proliferation.
Vehicle-treated control cells (black bars); and cells treated with 10 µM (white
bars); 5 µM (medium gray bars); 2.5 µM (light gray bars); 1 µM (dark gray
bars). Data shown are representative of 3 independent experiments performed
in duplicate (means ± SE) showing similar results (*P<0.05).

FC101 induces glioblastoma cell death via apoptosis. To
determine the mechanisms underlying the cytotoxic cellular
response described above, we assessed the involvement of
programmed cell death-associated signaling proteins and
oxidative stress-related molecules in response to FC101.
PARP, an enzymatic protein that plays a role in DNA
repair and a downstream target of caspases, which mediate
programmed cell death, was examined as an indicator
of apoptosis in glioblastoma cells treated with FC101.
Immunoblotting procedures revealed that the glioblastoma
cells exposed to 1 µM FC101 produced cleaved PARP protein
expression, a marker of cells undergoing apoptosis (Fig. 3),
while no changes in caspase-9 protein expression, an initiator
caspase, were observed (Fig. 3). Additionally, ROS, known
inducers of death receptor and mitochondrial-mediated apoptosis in cancer cells, were also examined as a mechanistic
contributor to FC101-induced glioblastoma cell death. To this
end, we observed a modest increase in the hydrogen peroxide
concentration in the A172 cells treated with FC101 as
compared to the vehicle-treated control cells, while the U251
cells displayed a decrease in hydrogen peroxide concentration
following treatment with FC101 (Fig. 4). Taken together, these
data demonstrate that FC101 induces a differential oxidative
stress response that is cell type-dependent and that this fungal
metabolite promotes apoptotic cell death in glioblastoma cells
via caspase signaling.
Inhibition of glioblastoma cell migration. Glioblastomas are
highly invasive tumors that ultimately result in high rates of
disease recurrence. Therefore, in this study, we analyzed the
ability of FC101 to affect glioblastoma cell migration and
structural proteins involved in this cellular process. α-actinin 1
and 4, actin-binding proteins with an established role in cell
migration (13,14) and shown to be expressed at high levels

Figure 2. Time-course analysis of fusarochromanone (FC101)-treated glioblastoma cells. Glioblastoma cells underwent cytotoxity-associated cell death in
response to 1 µM FC101 (square), as compared to the vehicle-treated control
cells (diamond). Shown is an experiment representative of 3 independent
experiments performed in duplicate (means ± SE) that displayed similar results.

Figure 3. Fusarochromanone (FC101) induces apoptotic cell death. FC101 promoted programmed cell death as indicated by the expression of cleaved PARP
in the A172 and U251 cells treated with 1 µM FC101 for 24 h. Immunoblots
shown are representative of 3 independent experiments that showed similar
results.

in glioblastomas as compared to normal brain tissue (14),
were examined in the FC101-treated glioblastoma cells.
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Figure 4. Detection of ROS in A172 (triangle) and U251 (square) cells treated
with 1 µM fusarochromanone (FC101) for 24 h as determined by measuring
H2O2 concentration. H2O2 standard serial dilution (diamond); vehicle-treated
control cells (solid symbols); cells treated with 1 µM FC101 (open symbols).
Data displayed is an average of 3 separate independent experiments.
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Figure 6. Fusarochromanone (FC101) impairs glioblastoma cell migration.
Glioblastoma cell migration was significantly (*P<0.05) diminished in the
U251 cells treated with 1 µM FC101 for 24 h. Data shown are representative
of 3 independent experiments performed in duplicate (means ± SE) showing
similar results.(A) Vehicle-treated control cells (black bars); (B) cells treated
with 1 µM FC101 for 24 h (white bars).

that 1 µM FC101 induced a 46% decrease (P<0.05) in glioblastoma cell migration as compared to the vehicle-treated control
cells (Fig. 6). These results are in accordance with the findings
of a recent study by Bury et al (15), that also showed that the
fungal metabolite, fusicoccin A, impaired the migratory and
invasion ability of glioblastoma cells.
Discussion

Figure 5. ELISA of α-actinin 1 and 4 (α-act1 and α-act4) in A172 and U251
cells 24 h post-exposure to 1 µM fusarochromanone (FC101). Data displayed
are an average (means ± SE) of 3 separate independent experiments. Vehicletreated control cells (black bars); cells treated with 1 µM FC101 for 24 h
(white bars).

Using immunoenzyme linked assays, a moderate increase in
α-actinin 1 and 4 expression was observed in the U251 cells
exposed to FC101 when compared to the vehicle-treated
control cells, while a diminutive decrease in α-actinin 1
and 4 expression was observed in the A172 cells treated with
FC101 (Fig. 5). Subsequently, cell migration assays revealed

Fungal metabolites are emerging as promising anticancer
agents for the treatment of human cancers, in part, since they
are naturally derived products. However, the utility of metabolic products from fungi as adjuvant or neoadjuvant agents
for the treatment of brain tumors, specifically glioblastomas,
has received little attention. To date, the most well characterized fungal metabolite exhibiting cytotoxic anticancer activity
in glioblastomas is the fumonisin, fumonisin B1, which exerts
its biological effects by interfering with sphingolipid metabolism (10-12). Additionally, studies on the fungal metabolites,
brefeldin A and ophiobolin A, which impair the structure
and functions of the Golgi apparatus and calmodulin, respectively, have also shown that they promote glioblastoma cell
death (9,16). Collectively, these studies establish the cytotoxic
antitumor effects of fungi-produced metabolites in glioblastomas by affecting a range of biological processes.
In this study, we demonstrated that the fungal metabolite,
FC101, exhibited antitumorigenic affects in glioblastomas as
a consequence of inducing cell death. This was supported by
cell proliferation data from the present study that displayed an
IC90 in glioblastomas treated with 1 µM FC101 and examined
4 days later. Our findings are in accordance with those from
other studies on breast, melanoma and bladder cancers, that
also showed that therapeutic applicable concentrations of
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FC101 were effective at promoting tumor cell killing in these
human cancers (7,8). In this study, it was also determined that
FC101 induced caspase-dependent apoptotic glioblastoma
cell death, as indicated by PARP cleavage, a caspase target.
This is consistent with data from other studies on melanomas
and breast cancer, that also demonstrated caspase-dependent
apoptosis as the underlying mechanism of tumor cell death
observed in these cancers in response to FC101 [(8) and study
by Mahdavian et al (unpublished data)]. Although PARP
cleavage provided substantial evidence that FC101 promoted
caspase-dependent apoptotic glioblastoma cell death, changes
in caspase-9 protein expression were not detected. The lack
of an affect on caspase-9 expression supports the notion that
FC101 does not induce apoptotic cell death in glioblastomas
via an intrinsic mechanism, as suggested in in another study of
ours [Mahdavian et al (unpublished data)], which showed that
FC101 had no effect on intrinsic apoptotic pathway proteins
(BAD, BAK and BAX) in breast cancer cells. In addition to
caspase signaling, oxidative stress has also been shown to act
as a mechanistic contributor of fungal metabolite-induced
apoptotic cell death (10,11,17,18). Stockmann-Juvala et al (10)
and Chaudhari et al (17) demonstrated that fumonisin B1 and
the trichothecene, T-2 toxin, elicited apoptotic cell death as
a consequence of increased ROS production and reduced
glutathione levels in cervical cancer and glioblastomas,
respectively. However, the assessment of oxidative stress in our
study revealed differential ROS levels in the A172 and U251
glioblastoma cells treated with FC101 as compared to the
control-treated cells, suggesting that variations in the genetic
backgrounds of these cells likely contribute to the divergent
responses observed and the role of oxidative stress in FC101induced apoptotic glioblastoma cell death.
In this study, we further demonstrated that FC101 also
exhibits antitumor properties in glioblastomas by abrogating
cell migration, a cell behavior that contributes to the metastatic
invasiveness of human cancers, ultimately leading to disease
recurrence. This observation is consistent with recent studies on
the fungal metabolites, fusicoccin A and chaetoglobosin A that
also had antimigratory effects on glioblastoma and leukemia
cells which were attributed to the impairment of the actin
cytoskeleton (15,19). However, in this study, the analysis here of
α-actinin 1 and 4, structural elements of the actin cytoskeleton
with well-characterized roles in cell migration were minimally
affected by exposure to FC101 (13,14). It should be stated that
although FC101 appeared to have little affect on α-actinin 1
and 4, the disruption of subcellular actin filament structures
(leading edge, trailing edge) important for cell migration may
underlie the affects of FC101 on glioblastosma cell migration,
even in the absence of significant changes in protein expression.
Additionally, the antimigratory response of glioblastomas to
FC101 may be causally related to the down-regulation of metalloproteinases, as observed in osteosarcomas and mesothelioma
cells treated with the fungal metabolites, 3-O-methylfunicone
and fucoxanthin(20,21). Furthermore, to the best of our knowledge, this is the first study that illustrates the antimigratory
effects of FC101 on tumor cells.
In the present study, we demonstrate the effectiveness of
FC101 as an anticancer agent in glioblastomas, expanding
its potential therapeutic utility for the treatment of human
cancers. The prospective application of FC101 for the treat-

ment of cancer is furthered by experimental studies that
demonstrate that cancer cells are more sensitive to this fungal
metabolite than normal tissue (7,8), suggesting that FC101
circumvents normal tissue toxicity. This therapeutic characteristic of FC101 is particularly advantageous when considering
neurotoxicity is often a limiting factor for chemotherapeutic
drugs used for the treatment of glioblastomas. Additional
caveats to the clinical treatment of these tumors is their therapeutic resistance attributed in part to high recurrence rates that
have made combinatorial therapy approaches essential for the
management and treatment of this disease. FC101 represents a
novel compound that can be explored for its therapeutic applications as a combinatorial agent that augments surgical and
radiotherapy approaches for the treatment of glioblastomas.
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